ACRIVON THERAPEUTICS INC (ACRV)

Company Profile

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2022-11-15. The firm uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Company Info

ACRIVON THERAPEUTICS INC

480 Arsenal Way, Suite 100

Watertown MASSACHUSETTS

P: 16172078979

Employees: 60

Website: https://acrivon.com/